Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIP: Gemcitabine + vandetanib vs gemcitabine in advanced pancreatic cancer
2010-021951-26Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (2 arms), sponsored by University of Liverpool. Primary endpoint: Overall survival. Started Feb 2011; status: completed.
02
Drugs
vandetanib
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2010-021951-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021951-26.